Investor Profile: Hercules Capital — Thesis, Cheque Size & How to Apply

Hercules Capital, Inc., listed on the New York Stock Exchange as HTGC, is a San Mateo-based specialty finance company and the largest non-bank venture lender in the United States. It is not a traditional venture fund: it provides senior secured venture growth loans to venture-backed companies, letting founders raise capital without selling as much equity. For founders needing runway, Hercules Capital funding is often the debt complement to an equity round.

Investment thesis

The thesis is that venture-backed companies need non-dilutive capital between equity rounds, and a specialist lender underwrites that risk better than a generalist bank. It provides structured debt, typically first-lien senior secured floating-rate loans with warrant coverage, to companies with strong backing, proven models, and clear paths to profitability, with terms customised per borrower.

Sectors and stages

Hercules Capital lends to venture, growth, and established-stage companies across technology and life sciences. In technology it covers software, artificial intelligence, cybersecurity, and deep technology; in life sciences, therapeutics, diagnostics, and devices. The right moment, in its own guidance, is after product-market fit, with recurring revenue growth, when capital is needed to scale or extend runway without extra dilution.

Fund size and cheque size

As a publicly traded business development company, Hercules Capital raises no single closed venture fund, so no traditional fund size is publicly disclosed. Its scale is cumulative lending: in October 2025 it passed $25 billion in total debt commitments since 2004, to more than 700 companies. It reported about $5.5 billion of assets under management at the end of the third quarter of 2025. Independent profiles report facilities generally between $20 million and $40 million, negotiated case by case. Its arm Hercules Adviser manages around $1.6 billion across four institutional funds.

Notable portfolio

Hercules Capital has financed more than 700 companies backed by over 1,000 venture capital and private equity sponsors. Names include Box and Trulia; Tapjoy has praised its growth-stage understanding. Recent borrowers include Marathon Health and Dyne Therapeutics; in 2026 Beren Therapeutics announced up to $165 million from Hercules alongside a $135 million equity round.

Partners

Hercules Capital is led by Scott Bluestein, chief executive officer and chief investment officer, with Seth Meyer as president and Andrew Olson as chief financial officer. Its technology lending is led by Steve Kuo, who has led over $1.2 billion in investments at the firm. James Downing leads origination in Europe from London. Its team exceeds 60 investment professionals.

Programs, credits and perks

Hercules Capital does not offer an accelerator, a credits catalogue, or equity-style perks, and founders should not approach it expecting either. Its value is financial: non-dilutive capital that extends runway and preserves ownership while milestones are reached. It also runs the Ventured Growth podcast. The closest thing to a programme is the lending relationship itself, with follow-on financings and refinancings towards an exit.

How to apply for funding

There is no equity-style portal, so learning how to get funding from Hercules Capital usually starts with a sponsor introduction or a direct approach to the lending team. The firm publishes [email protected] and 650.289.3060 for financing enquiries. Arrive with venture backing, a clear use of proceeds, and a realistic view of covenants and repayment. Because this is secured debt, the conversation will focus on cash flow and milestones, not vision alone.